About Us
Founded in 1944, the American Committee for the Weizmann Institute of Science develops philanthropic support for the Weizmann Institute in Israel, and advances its mission of science for the future of humanity.
https://www.weizmann-usa.org/news-media/feature-stories/what-s-new-in-brain-research-at-weizmann/
Jun 10, 2019...
Weizmann Institute researchers from across the disciplines are pursuing topics in neuroscience, approaching this crucial field from a number of angles. That’s because understanding our brains – in both health and disease – benefits everyone on this planet.
From Alzheimer’s to autism, Parkinson’s to mental health, memory to aging and beyond, here are just some of the Institute’s neuroscience advances over just the past year:
Feb 21, 2012...
The students in Allison Granberry’s class at Hostos-Lincoln Academy, a South Bronx public school serving children in grades 6 to 12, are as excited about proteins and other biological macromolecules as most kids their age are about playing basketball or updating their Facebook status.
The passion of these newly minted scientists is due to the enthusiasm of Ms. Granberry, as well as Prof. Joel L. Sussman of the Department of Structural Biology at the Weizmann Institute of Science in Rehovot, Israel. In a Rockefeller University after–school outreach program called SMART (Students Modeling A Research Topic) Team—a nationwide project conceived by Dr. Timothy Herman, Director of the Center for Biomolecular Modeling at the Milwaukee School of Engineering—Ms. Granberry and her students work with Prof. Sussman’s website Proteopedia (proteopedia.org).
Feb 10, 2014...
Schwartz’s research questions assumptions about the central nervous system.
Imagine being able to inhibit or reverse a universal affliction – brain degeneration – and specific diseases or physical injuries that cause its sudden onset. This is precisely what Prof. Michal Schwartz has spent the last two decades studying, with revolutionary results.
Schwartz is far from the stereotypical “mad scientist.” Pretty and petite, with a cascade of curls, she rushes down the hallway of her office and adjacent laboratory more like a student late for a class than an international award-winning powerhouse whose research has turned pre-existing dogma about the central nervous system on its head.
https://www.weizmann-usa.org/news-media/in-the-news/immune-system-maintains-brain-health/
Nov 01, 2016...
©ROY SCOTT/GETTY IMAGES
In a dark room in Charlottesville, Virginia, a mouse swims in a small pool, searching for a place to rest. In 12 previous swims, with the help of visual cues and training from an experimenter, the mouse eventually tracked down a platform near the center of the pool. But just a day after its last swim, the animal is spending nearly as much time searching for the platform as it did on its first swim. The discombobulated mouse’s problem? It has no T cells.
May 01, 2019...
Photo via Shutterstock.com
The State of Israel will soon turn 71. And yet this babe among nations ranks fifth internationally for average life expectancy and conducts some of the world’s most critical research on healthy aging.
That is the conclusion of “Longevity in Israel,” a new 575-page report from the London-based Aging Analytics Agency in cooperation with Vetek (Seniority) – The Movement for Longevity and Quality of Life and the Israeli Longevity Alliance.
Aug 02, 2019...
JERUSALEM, Aug. 1 (Xinhua) – Israeli scientists have discovered when and where mistakes occur in the cellular manufacture of proteins, which may help with Alzheimer’s and cancer researches, the Weizmann Institute of Science (WIS) reported Thursday.
The researchers not only succeeded in measuring the rate of such mistakes, but also revealed that the DNA contains a “mistake manual” of sorts that dictates where these mistakes need to be avoided and where they may be tolerated or even welcome.
Feb 19, 2006...
Approximately 18.8 million American adults suffer from depression, the leading cause of disability in the United States. Yet only about half the patients who take common medical treatments like antidepressant drugs actually see a therapeutic effect. Moreover, they suffer a broad range of undesirable side effects including weight gain, sexual dysfunction and even suicidal behavior.
Electroconvulsive therapy (ECT) has a far higher success rate, with some 80% of patients responding positively. ECT, however, is a highly invasive treatment involving general anesthesia, with many serious side effects ranging from dizziness and headaches to temporary or even permanent memory impairment.
https://www.weizmann-usa.org/news-media/feature-stories/understanding-alzheimer-s/
Jun 28, 2010... One in 10 Americans over the age of 65 has Alzheimer's disease, a debilitating neurological disorder that slowly destroys memory and cognitive function and for which there is no cure. According to the National Institutes of Health (NIH), because the risk of developing the disease increases with age and more people are living longer, the number of people suffering from Alzheimer's is likely to grow dramatically over the next few decades. Despite years of research by scientists all over the world, Alzheimer's is still poorly understood.
Apr 24, 2018...
Neuroscientist Michael Heneka knows that radical ideas require convincing data. In 2010, very few colleagues shared his belief that the brain’s immune system has a crucial role in dementia. So in May of that year, when a batch of new results provided the strongest evidence he had yet seen for his theory, he wanted to be excited, but instead felt nervous.
He and his team had eliminated a key inflammation gene from a strain of mouse that usually develops symptoms of Alzheimer’s disease. The modified mice seemed perfectly healthy. They sailed through memory tests and showed barely a sign of the sticky protein plaques that are a hallmark of the disease. Yet Heneka knew that his colleagues would consider the results too good to be true.
https://www.weizmann-usa.org/news-media/in-the-news/blood-test-for-alzheimer-s/
Feb 04, 2013...
A simple blood test could be on the way for diagnosing Alzheimer’s disease. Image via Shutterstock.com*
“Today one of the main weaknesses in the Alzheimer’s area is that patients don’t find out until it’s too late,” says Ilya Budik, CEO of NeuroQuest, an Israeli company developing a novel blood test for early detection of the most common cause of dementia worldwide.
“There are many new therapies under development, and the most successful trials are showing the earlier a patient is treated, the better likelihood of responding to the treatment,” he says.
©2023 American Committee for the Weizmann Institute of Science
